unknown
Stage
About
Flightpath Biosciences develops targeted bacterial deletion therapies designed to selectively eliminate harmful gram-negative bacteria to treat infection-driven complex diseases such as colorectal cancer, Lyme disease, periodontal disease, and women's health conditions without harming the surrounding microbiome.
Explore Flightpath Biosciences's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.